The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cost-effectiveness of universal screening for germline BRCA mutations in metastatic pancreatic cancer.
 
Myles Ingram
No Relationships to Disclose
 
Yoanna S Pumpalova
No Relationships to Disclose
 
Jiheum Park
No Relationships to Disclose
 
Francesca Lim
No Relationships to Disclose
 
Jennifer S. Ferris
No Relationships to Disclose
 
Susan Elaine Bates
Consulting or Advisory Role - PEGASCY; Scandion Oncology
Research Funding - Agios; Pfizer
Patents, Royalties, Other Intellectual Property - Deacetylase Inhibiton Therapy (Inst); Depsipeptide for Therapy of Kidney Cancer (Inst)
 
Gulam Abbas Manji
Stock and Other Ownership Interests - Gilead Sciences
Honoraria - Celgene; Exelixis; Roche/Genentech
Consulting or Advisory Role - BiolineRx; CEND Pharmaceuticals; Exelixis; Ipsen; Roche/Genentech
Research Funding - BiolineRx (Inst); Merck (Inst); Plexxikon (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Celgene; Exelixis; Roche/Genentech
 
Chung Yin Kong
No Relationships to Disclose
 
Chin Hur
Stock and Other Ownership Interests - Cambridge Biomedical and Economic Consulting Group
Honoraria - Exact Sciences; Kite, a Gilead company; Takeda Science Foundation